Clinical InvestigationRelationship Between High Circulating Adiponectin With Bone Mineral Density and Bone Metabolism in Elderly Males With Chronic Heart Failure
Section snippets
Study Design
Having reviewed medical history archives of the Cardiology Department, Clinical Medical Center Zvezdara Belgrade, first contacts with eligible patients were made on the phone. For the baseline visit we screened 152 males aged 55 years and above with CHF from ischemic or idiopathic dilated cardiomyopathy. Following the baseline visit, 73 patients were included all of whom met the study inclusion and exclusion criteria. Inclusion criteria were: 1. duration of CHF for longer than 1 year; 2.
Demographic and Clinical Characteristics of CHF Patients and Healthy Subjects
The general characteristics of CHF patients and healthy subjects are summarized in Table 1. Compared to healthy subjects, CHF patients have lower left ventricular ejection fraction, 6-minute walking distance and grip strength, but higher left ventricular diameter. No difference in waist, waist/hip ratio, and body mass index was found between CHF patients and healthy subjects.
Biohumoral Variables of CHF Patients and Healthy Subjects
The biohumoral variables are presented in Table 2. CHF patients had significantly higher serum adiponectin, NT-pro-BNP,
Discussion
As far as we know, this is the first report of an association between adiponectin with BMD and bone specific surrogates in CHF patients. Our main finding is that increased adiponectin levels were independently associated with hip BMD in elderly men with mild to moderate CHF. Moreover, increased adiponectin is positively correlated with bone specific surrogates (osteocalcin, β-CrossLaps, RANKL, and OPG) in CHF patients. These findings support the hypothesis that adiponectin may play a
Acknowledgments
We thank Mrs M. Argirovic from MSD for support during application procedure for educational grant. This work was also supported by biochemical laboratory “Zavod za laboratorijsku dijagnostiku Konzilijum” Belgrade.
References (37)
- et al.
Loss of bone mineral in patients with cachexia due to chronic heart failure
Am J Cardiol
(1999) - et al.
Markers of bone metabolism in congestive heart failure
Clin Chim Acta
(2006) Relationships among body mass, its components, and bone
Bone
(2002)- et al.
Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway
Exp Cell Res
(2005) - et al.
Adiponectin as a novel determinant of bone mineral density and visceral fat
Bone
(2003) - et al.
Influence of insulin-like growth factor-1 and leptin on bone mass in healthy postmenopausal women
Bone
(2001) - et al.
Wasting as independent risk factor for mortality in chronic heart failure
Lancet
(1997) - et al.
Echocardiography-guided interventions
J Am Soc Echocardiogr
(2009) - et al.
Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men
Clin Chim Acta
(2008) - et al.
A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms
Mol Cell Endocrinol
(2009)
Endocrine regulation of energy metabolism by the skeleton
Cell
Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass
Cell
Biomarkers in heart failure
N Engl J Med
Can adiponectin be a novel metabolic biomarker for heart failure?
Circ J
Femoral bone mineral density in patients with heart failure
Osteoporos Int
Relationship between body composition and bone mass in women
J Bone Miner Res
Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway
J Bone Miner Res
Adiponectin is a negative regulator of bone mineral and bone strenght in growing mice
Exp Biol Med (Maywood)
Cited by (36)
Causal association between heart failure and bone mineral density: Insights from a two-sample bidirectional Mendelian randomization study
2022, GenomicsCitation Excerpt :Both osteoporosis and HF are very common age-related syndromes that can lead to loss of independence in function and daily life, increasing time spent in bed and social burden. Studies have shown a downward trend in BMD and bone mineral content in noncachenic HF [12]. In addition, chronic HF can also cause severe bone loss, increasing the risk of osteoporosis and fractures [13].
Simultaneous fat and bone assessment in hospitalized heart failure patients using non-contrast-enhanced computed tomography
2016, Journal of CardiologyCitation Excerpt :These relationships might be the combined result of increased mechanical loading on the bone and the effects of adipokines or myokines [35]. Bozic et al. reported that plasma adiponectin levels are inversely associated with bone mineral density and positively associated with osteocalcin levels in HF patients [30]. In experimental studies, osteocytes/blasts have been found to regulate fat metabolism [6,36], and inversely, fat cells might regulate bone mass [7,37].
Metabolic impairment in heart failure: The myocardial and systemic perspective
2014, Journal of the American College of CardiologyMetabolism and the heart: An overview of muscle, fat, and bone metabolism in heart failure
2013, International Journal of CardiologyCitation Excerpt :In animal models, osteocalcin acts on adipocytes to induce adiponectin secretion, which secondarily reduce insulin resistance [129]. It is interesting that our recent finding of positive association between adiponectin and osteocalcin in HF patients is in accordance with this revealed cross regulation between bone and energy metabolism [83]. A recent study demonstrated that ‘adipose-to-muscle interaction’ is a two-way street [130].
Relation between bone mineral density, bone loss and the risk of cardiovascular disease in a Chinese cohort
2012, American Journal of CardiologyCitation Excerpt :Leptin increases the differentiation of bone marrow stromal cells into osteoblasts and inhibits generation of osteoclasts. Leptin administration increases bone formation, BMD, and expression of osteogenic genes.21 Adiponectin, another adipocyte-devised hormone, acts as an antiatherogenic and anti-inflammatory molecule.
Supported by Serbian Ministry of Science (grant 145019), by Merck Sharp & Dohme unrestricted educational grant and by biochemical laboratory “Zavod za laboratorijsku dijagnostiku Konzilijum” Belgrade.